Alpha Score of 41 reflects weak overall profile with poor momentum, moderate value, weak quality, moderate sentiment.
Danaher Corporation (DHR) closed the session reflecting a cautious market stance as investors weigh its current valuation against recent financial performance. The stock is trading within its 52-week range of $174.64 to $242.05, currently pressured by a high P/E ratio of 86.35. Financial data reveals a challenging growth environment, with year-over-year revenue growth at 2.9% and EPS growth contracting by 4.5%. With an EPS of 2.3 and a net margin of 14.7%, the company faces efficiency hurdles that weigh on its overall Alpha Score of 45.6. Internal metrics highlight a divergence between momentum and quality. The momentum sub-score of 55.1 suggests some relative stability in trading activity, yet the quality sub-score of 45.9 reflects the impact of the current earnings decline. The value sub-score sits at 50, indicating that the market remains undecided on the stock's price relative to its fundamental output. Moving forward, market participants should monitor whether the company can improve its net margins and reverse the negative EPS growth trend throughout the remainder of the quarter.
| Fund | Shares Held | Position Value | Action (latest Q) |
|---|---|---|---|
| Citadel Ken Griffin | 2.73M | $625.03M | NEW |
| Point72 Steve Cohen | 1.74M | $399.21M | NEW |
| D.E. Shaw David Shaw | 543K | $124.41M | NEW |
| Blackstone | 16K | $3.59M | NEW |
Danaher Corporation designs, manufactures, and markets professional, medical, research, and industrial products and services globally, with a primary focus on the United States, China, and other international markets. Operating through three key segments—Biotechnology, Life Sciences, and Diagnostics—the company provides bioprocessing technologies, consumables, and solutions that accelerate therapeutic development and manufacturing, including cell culture media, chromatography resins, filtration systems, and single-use hardware for full manufacturing suites. Its Life Sciences division supports advanced research tools, while Diagnostics offers essential testing and healthcare filtration solutions. Originally founded in 1969 and transformed through strategic acquisitions and divestitures, such as the 2023 spin-off of its environmental solutions into Veralto, Danaher now concentrates on scientific instruments and consumables in the diagnostics and research sector. Employing around 62,000 to 63,000 people under CEO Rainer Blair, Danaher plays a pivotal role in the healthcare and life sciences industries, driving innovation in biopharma production and medical diagnostics with a strong emphasis on recurring revenue streams.
Earnings calendar coming soon. Subscribe to get notified when DHR reports next.
Get earnings alerts →